Emerging opportunities for antipsychotic drug discovery in the postgenomic era.
about
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and FutureTC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.D-amino acid oxidase activity is inhibited by an interaction with bassoon protein at the presynaptic active zone.
P2860
Emerging opportunities for antipsychotic drug discovery in the postgenomic era.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging opportunities for antipsychotic drug discovery in the postgenomic era.
@en
Emerging opportunities for antipsychotic drug discovery in the postgenomic era.
@nl
type
label
Emerging opportunities for antipsychotic drug discovery in the postgenomic era.
@en
Emerging opportunities for antipsychotic drug discovery in the postgenomic era.
@nl
prefLabel
Emerging opportunities for antipsychotic drug discovery in the postgenomic era.
@en
Emerging opportunities for antipsychotic drug discovery in the postgenomic era.
@nl
P2093
P356
P1476
Emerging opportunities for antipsychotic drug discovery in the postgenomic era.
@en
P2093
Lars J S Knutsen
Michael J Marino
Michael Williams
P304
P356
10.1021/JM701094Q
P407
P577
2008-01-17T00:00:00Z